Fulltext

Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide

Boubaker, Ariane ; Prior, John ; Willi, Jean-Pierre ; Champendal, Melanie ; Kosinski, Marek ; Bischof Delaloye, Angelika ; Maecke, Helmut ; Ginj, Mihaela ; Baechler, Sébastien ; Buchegger, Franz

In: European Journal of Nuclear Medicine and Molecular Imaging, 2012, vol. 39, no. 12, p. 1868-1875

Ajouter à la liste personnelle
    Titre
    • Biokinetics and dosimetry of 111In-DOTA-NOC-ATE compared with 111In-DTPA-octreotide
    Auteur
    • Boubaker, Ariane. Department of Nuclear Medicine, Lausanne University Hospital, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    • Prior, John. Department of Nuclear Medicine, Lausanne University Hospital, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    • Willi, Jean-Pierre. Department of Nuclear Medicine, University Hospital of Geneva, Geneva 14, Switzerland
    • Champendal, Melanie. Department of Nuclear Medicine, Lausanne University Hospital, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    • Kosinski, Marek. Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland
    • Bischof Delaloye, Angelika. Department of Nuclear Medicine, Lausanne University Hospital, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    • Maecke, Helmut. Department of Nuclear Medicine, University Hospital of Freiburg, Freiburg, Germany
    • Ginj, Mihaela. Joint Department of Medical Imaging, University Health Network, Toronto, ON, Canada
    • Baechler, Sébastien. Institute of Radiation Physics, Lausanne University Hospital, Lausanne, Switzerland
    • Buchegger, Franz. Department of Nuclear Medicine, Lausanne University Hospital, CHUV, Rue du Bugnon 46, 1011, Lausanne, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • European Journal of Nuclear Medicine and Molecular Imaging, 2012, vol. 39, no. 12, p. 1868-1875. Springer-Verlag
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:314001
    Summary
    Purpose: The biokinetics and dosimetry of 111In-DOTA-NOC-ATE (NOCATE), a high-affinity ligand of SSTR-2 and SSTR-5, and 111In-DTPA-octreotide (Octreoscan™, OCTREO) were compared in the same patients. Methods: Seventeen patients (10 men, 7 women; mean age 60years), referred for an OCTREO scan for imaging of a neuroendocrine tumour (15), thymoma (1) or medullary thyroid carcinoma (1), agreed to undergo a second study with NOCATE. Whole-body anterior-posterior scans were recorded 0.5 (100% reference scan), 4, 24 and 48h (17 patients) and 120h (5 patients) after injection. In 16 patients the OCTREO scan (178 ± 15MBq) was performed 16 ± 5days before the NOCATE scan (108 ± 14MBq) with identical timing; 1 patient had the NOCATE scan before the OCTREO scan. Blood samples were obtained from 14 patients 5min to 48h after injection. Activities expressed as percent of the initial (reference) activity in the whole body, lung, kidney, liver, spleen and blood were fitted to biexponential or single exponential functions. Dosimetry was performed using OLINDA/EXM. Results: Initial whole-body, lung and kidney activities were similar, but retention of NOCATE was higher than that of OCTREO. Liver and spleen uptakes of NOCATE were higher from the start (p < 0.001) and remained so over time. Whole-body activity showed similar α and β half-lives, but the β fraction of NOCATE was double that of OCTREO. Blood T 1/2β for NOCATE was longer (19 vs. 6h). As a result, the effective dose of NOCATE (105μSv/MBq) exceeded that of OCTREO (52μSv/MBq), and the latter result was similar to the ICRP 106 value of 54μSv/MBq. Differential activity measurement in blood cells and plasma showed an average of <5% of NOCATE and OCTREO attached to globular blood components. Conclusion: NOCATE showed a slower clearance from normal tissues and its effective dose was roughly double that of OCTREO